Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)

BACKGROUND AND AIMS: Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characterized by the formation of abnormal triglyceride- and cholesterol-rich lipoproteins (remnant particles). Patients with FDBL have a high risk for atherosclerotic disease. The effect of PCSK9 inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldmann, Elisa, Wu, Liya, Busygina, Kristina, Altenhofer, Julia, Henze, Kerstin, Folwaczny, Alexander, Parhofer, Klaus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942248/
https://www.ncbi.nlm.nih.gov/pubmed/35320320
http://dx.doi.org/10.1371/journal.pone.0265838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942248/
https://www.ncbi.nlm.nih.gov/pubmed/35320320
http://dx.doi.org/10.1371/journal.pone.0265838

Ejemplares similares